z-logo
open-access-imgOpen Access
Symptomatic Hyponatremia in a Patient With Hepatorenal Syndrome Treated with Terlipressin.
Author(s) -
Raheel Ahmed,
Tanveer Ahmed,
Syed Munib
Publication year - 2022
Publication title -
pakistan journal of kidney diseases
Language(s) - English
Resource type - Journals
eISSN - 2708-3020
pISSN - 2617-0329
DOI - 10.53778/pjkd61181
Subject(s) - terlipressin , hepatorenal syndrome , medicine , hyponatremia , hypertonic saline , kidney disease , acute kidney injury , gastroenterology , cirrhosis
Terlipressin (vasopressin analogue) is considered most promising pharmacotherapy used for reversal of hepatorenal syndrome and esophageal variceal bleed. It occasionally results in hyponatremia, often complicated by serious central nervous system manifestation. We report here a case of a 60 years’ old female known case of chronic liver disease decompensated who presented with acute kidney injury secondary to hepatorenal syndrome. Treatment was started with terlipressin loading dose followed by maintenance dose. She developed acute confusion, however there was no obvious brain pathology on computed tomography. Her baseline serum sodium (146.8mol/L) decreased to 111.5mmol/L after terlipressin was initiated.  Terlipressin was withdrawn and responded to 3% hypertonic saline. Terlipressin-induced hyponatremia may be a rare complication and treating physicians should be aware of the possible complications arising during the management of hepatorenal syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here